Drug Interaction Report

GENERALLY AVOID: The concomitant use of HMG-CoA reductase inhibitors and the fiber pectin may result in increased levels of low-density lipoprotein cholesterol. The beneficial effect of the HMG-CoA reductase inhibitor may be reduced. The mechanism is decreased gastrointestinal absorption by the fiber. A case report exists for lovastatin. A similar reaction may occur with other HMG-CoA reductase inhibitors, although data is lacking.

MANAGEMENT: The clinician should consider avoiding coadministration, but if this is not possible the administration times should be separated as much as possible. Patients should be monitored for altered cholesterol-lowering effects.